Genesis Healthcare, Inc., together with its subsidiaries, owns and operates skilled nursing facilities and assisted/senior living facilities in the United States. The company operates through three segments: Inpatient Services, Rehabilitation Therapy Services, and All Other Services. It also provides a range of rehabilitation therapy services, including speech-language pathology, physical therapy, occupational therapy, and respiratory therapy. In addition, the company offers other specialty medical services, such as physician, staffing, and other healthcare related services. As of December 31, 2017, it provided inpatient services through a network of 470 skilled nursing and assisted/senior living facilities, including 444 skilled nursing facilities and 26 stand-alone assisted/senior living facilities across 30 states. Genesis HealthCare, Inc. also supplied rehabilitation and respiratory therapy to approximately 1,600 healthcare locations in 46 states and the District of Columbia. The company was formerly known as FC-GEN Operations Investment, LLC and changed its name to Genesis HealthCare, Inc. in February 2015. Genesis HealthCare, Inc. was founded in 2003 and is headquartered in Kennett Square, Pennsylvania.
Industry, Sector and Symbol
Industry Skilled nursing care facilities
Sub-IndustryN/A
SectorMedical
Phone610-444-6350
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.37 billion
Profitability
Miscellaneous
Employees68,700
OptionableOptionable
Genesis Healthcare (NYSE:GEN) Frequently Asked Questions
What is Genesis Healthcare's stock symbol?
Genesis Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "GEN."
How were Genesis Healthcare's earnings last quarter?
Genesis Healthcare Inc (NYSE:GEN) announced its quarterly earnings data on Wednesday, November, 7th. The company reported ($0.57) EPS for the quarter, missing the Zacks' consensus estimate of ($0.32) by $0.25. The company earned $1.22 billion during the quarter, compared to analysts' expectations of $1.21 billion. During the same quarter last year, the firm posted ($0.34) EPS. View Genesis Healthcare's Earnings History.
When is Genesis Healthcare's next earnings date?
What price target have analysts set for GEN?
4 Wall Street analysts have issued twelve-month target prices for Genesis Healthcare's shares. Their predictions range from $1.75 to $7.00. On average, they expect Genesis Healthcare's share price to reach $3.3125 in the next year. This suggests a possible upside of 108.3% from the stock's current price. View Analyst Price Targets for Genesis Healthcare.
What is the consensus analysts' recommendation for Genesis Healthcare?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genesis Healthcare in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genesis Healthcare.
Has Genesis Healthcare been receiving favorable news coverage?
News coverage about GEN stock has been trending neutral on Monday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Genesis Healthcare earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave news articles about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are some of Genesis Healthcare's key competitors?
Some companies that are related to Genesis Healthcare include Epizyme (EPZM), Intersect ENT (XENT), Regis Healthcare (REG), NationalResearchCorp . (NRC), BioCryst Pharmaceuticals (BCRX), OrganiGram (OGI), Alder Biopharmaceuticals (ALDR), Editas Medicine (EDIT), Fate Therapeutics (FATE), Kiniksa Pharmaceuticals (KNSA), Natera (NTRA), Cryolife (CRY), Tricida (TCDA), Coherus Biosciences (CHRS) and Green Organic Dutchman (TGOD).
Who are Genesis Healthcare's key executives?
Genesis Healthcare's management team includes the folowing people:
- Mr. George V. Hager Jr., CEO & Director (Age 63)
- Mr. Thomas DiVittorio, CFO, Sr. VP, Treasurer & Assistant Sec. (Age 51)
- Mr. Paul David Bach, COO & Exec. VP (Age 60)
- Dr. JoAnne Susan Reifsnyder Ph.D., MSN, MBA, FAAN, Exec. VP of Clinical Operations & Chief Nursing Officer (Age 60)
- Mr. Richard L. Castor, Chief Information Officer & Sr. VP (Age 64)
Who are Genesis Healthcare's major shareholders?
Genesis Healthcare's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include First Washington CORP (2.07%), BlackRock Inc. (2.01%), Columbia Pacific Advisors LLC (2.00%), Acadian Asset Management LLC (1.05%), Prescott Group Capital Management L.L.C. (0.58%) and Northern Trust Corp (0.41%). Company insiders that own Genesis Healthcare stock include Daniel Allen Hirschfeld, David A Reis, Joanne Susan Reifsnyder, Michael Scott Sherman, Paul David Bach, Stephen Scott Young and Thomas Divittorio. View Institutional Ownership Trends for Genesis Healthcare.
Which institutional investors are selling Genesis Healthcare stock?
GEN stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., First Washington CORP, Virtu Financial LLC and Northern Trust Corp. Company insiders that have sold Genesis Healthcare company stock in the last year include David A Reis, Joanne Susan Reifsnyder, Michael Scott Sherman, Paul David Bach, Stephen Scott Young and Thomas Divittorio. View Insider Buying and Selling for Genesis Healthcare.
Which institutional investors are buying Genesis Healthcare stock?
GEN stock was bought by a variety of institutional investors in the last quarter, including Prescott Group Capital Management L.L.C., Millennium Management LLC, Acadian Asset Management LLC, RBF Capital LLC, Mackay Shields LLC, Columbia Pacific Advisors LLC, California Public Employees Retirement System and Geode Capital Management LLC. View Insider Buying and Selling for Genesis Healthcare.
How do I buy shares of Genesis Healthcare?
Shares of GEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Genesis Healthcare's stock price today?
One share of GEN stock can currently be purchased for approximately $1.59.
How big of a company is Genesis Healthcare?
Genesis Healthcare has a market capitalization of $257.07 million and generates $5.37 billion in revenue each year. The company earns $-578,980,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Genesis Healthcare employs 68,700 workers across the globe.
What is Genesis Healthcare's official website?
How can I contact Genesis Healthcare?
Genesis Healthcare's mailing address is 101 EAST STATE STREET, KENNETT SQUARE PA, 19348. The company can be reached via phone at 610-444-6350 or via email at [email protected]
MarketBeat Community Rating for Genesis Healthcare (NYSE GEN)
MarketBeat's community ratings are surveys of what our community members think about Genesis Healthcare and other stocks. Vote "Outperform" if you believe GEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
